Trends in pioglitazone use among US adults with type 2 diabetes and suspected non-alcoholic fatty liver disease.
ConclusionsThe prevalence of T2D with suspected NALFD increased among US adults, but pioglitazone use decreased significantly over 2003-2016. Our study suggested a missed opportunity to prevent a future epidemic of cirrhosis due to NAFLD in patients with T2D.
PMID: 31829750 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
More News: Actos | Alcoholism | Cirrhosis | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Epidemics | Epidemiology | Fatty Liver Disease (FLD) | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Study | Urology & Nephrology